NSEBSE

There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.

Max

Open2,380

High2,389.8

Low2,342

Prev. Close2,380

Avg. Traded Price2,364.21

Volume72,395

MARKET DEPTH

Total bid41836.00

Total ask26512.00

Orders	Qty	Bid
1	1	2375.4
2	9	2375.3
4	7	2375.2
2	11	2375.1
1	8	2375

Ask	Qty	Orders
2376.7	2	4
2376.8	1	2
2376.9	2	3
2377	1	2
2377.1	2	10

HIGH/LOW

52w

LOW/HIGH

₹2342.0034 minutes ago

₹2389.80an hour ago

LOWER/UPPER CIRCUITS

₹2142.00

₹2618.00

Mankind Pharma Limited Stock performance

KEY OBSERVATIONS

positive

negative

neutral

Annual Revenue,rose 14.85%, in the last year to ₹14,636.43 Cr. Its sector's average revenue growth for the last fiscal year was 12.19%.

Quarterly Revenue,rose 12.89% YoY to ₹4,075.59 Cr. Its sector's average revenue growth YoY for the quarter was 15.52%.

Quarterly Net profit,rose 29.6% YoY to ₹568.06 Cr. Its sector's average net profit growth YoY for the quarter was 10.31%.

STOCK RETURNS

Versus Nifty 50

1 w

-0.15%

+0.69%

1 mth

+7.85%

-4.22%

3 mth

-1.08%

-6.65%

6 mth

+22.54%

-1.5%

1 yr

+0.78%

-9.29%

3 yr

+38.93%

+15.89%

5 yr

+28.03%

About Mankind Pharma Limited

Mankind Pharma Limited is one of India’s leading pharmaceutical companies, founded in 1991 and commencing operations in 1995. The Company develops, manufactures and markets a broad range of pharmaceutical formulations across acute and chronic therapies, along with consumer healthcare products including condoms, pregnancy detection kits, antacid powders, vitamin and mineral supplements, oral contraceptives and medicated anti-acne preparations.

The Company has established a strong domestic presence and expanded globally with subsidiaries in the US, Singapore, the UAE, Germany, Malaysia and the Philippines. A major milestone was the acquisition of Bharat Serums and Vaccines (BSV) in October 2024, strengthening its position in super-specialty therapies and women’s health. As on March 31, 2025, Mankind Pharma had 38 subsidiaries as per the consolidated financial statements.

Mankind operates 32 manufacturing facilities and 6 R&D centres, with more than 75% in-house manufacturing and over 95% local procurement of raw materials. The Company has an installed capacity of 44+ billion units and employs 5,100+ manufacturing staff and 730 scientists, including 73 PhDs. Its distribution is supported by 16,000+ stockists, a 17,700+ strong field force, and coverage of over 5 lakh doctors.

Business Segment of Mankind Pharma Limited

Therapy-wise sales mix (FY 2024-25): Cardiovascular 15%, Anti-Infectives 14%, Gynaecology 10%, Gastrointestinal 10%, Anti-Diabetic 8%, VMN 8%, Respiratory 7%, Dermatology 5%, Urology 5%, Pain/Analgesics 4%, Neuro/CNS 2%, Others 10%. The top five therapies contributed 57% of overall sales.
Geography: Domestic 87%, International 13%.
Consumer Healthcare contributed 7% to overall business.

Mankind Pharma Limited’s Key Management Team

Ramesh Juneja – Chairman & Whole Time Director
Rajeev Juneja – Vice Chairman & Managing Director
Sheetal Arora – Chief Executive Officer & Whole Time Director
Satish Kumar Sharma – Whole Time Director
Arjun Juneja – Chief Operating Officer
Ashutosh Dhawan – Global Chief Financial Officer
Hitesh Kumar Jain – Company Secretary & Compliance Officer (effective January 9, 2025)

Latest Updates on Mankind Pharma Limited

Acquisition: The Company acquired 100% stake in Bharat Serums and Vaccines Limited on October 23, 2024, for ₹13,768 crore, consolidating its presence in critical care, fertility and super-specialty therapies.
Digital transformation: Implemented initiatives such as PACE (procurement digitisation), Wave (distribution optimisation), and Superman SFA (GenAI-powered CRM), with IoT-enabled shopfloors and a Zero Trust cybersecurity framework.
Awards and recognitions: Excellence in Pharma Environmental Sustainability Award, Golden Peacock OHS Award (Paonta Sahib Unit), ASSOCHAM Pharma Excellence Award, and Deal Maker Award (Business Today) for Ramesh Juneja.
Product expansion: Entered the Gonadotrophins (IVF) segment via BSV acquisition, scaled PCOS and Iron portfolios, launched FCM in Gynaecology, and in-licensed brands such as Symbicort in Respiratory and advanced anti-infective injectables.

Similar stocks

SUNPHARMA₹1771.30+11.50 (0.65%)

DIVISLAB₹9373.50+12.50 (0.13%)

TORNTPHARM₹4646.00+28.90 (0.63%)

ZYDUSLIFE₹1120.00+8.00 (0.72%)

LAURUSLABS₹2031.20+33.30 (1.67%)

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

What is the share price of Mankind Pharma Limited?

As of 09 Oct 2026, the share price of Mankind Pharma Limited is ₹2,377.20 on the NSE and ₹2,376.85 on the BSE. The stock opened at ₹2,500.90, touched a high of ₹2,389.80 and a low of ₹2,342.00 during today's session.

How much return has Mankind Pharma Limited given in the last 6 months?

Over the last 6 months, Mankind Pharma Limited has given a return of 15.86%. The stock was priced at ₹2,054.20 on 09 Apr 2026 and has Rise to ₹2,377.20 as of 09 Oct 2026, a change of ₹323.00 per share.

What were the most recent reported sales and net income of Mankind Pharma Limited?

For Q1 FY27, Mankind Pharma Limited reported: Revenue (Net Sales): ₹29640.50 Cr - Up 14.80% year-on-year from ₹25818.20 Cr in Q4 FY26. Net Income (PAT): ₹5584.90 Cr - Down -21.74% year-on-year from ₹7136.10 Cr in Q4 FY26.

What was Mankind Pharma Limited's low today on the NSE?

The intraday low for Mankind Pharma Limited on the NSE today was ₹2,342.00. The stock's 52-week low stands at ₹1,909.70, recorded on 23 Mar 2026. Today's low is 22.64% above the 52-week low, indicating the stock is trading well above its yearly lows.

How much return has Mankind Pharma Limited given in the last 3 months?

Mankind Pharma Limited has delivered a return of -6.00% over the last 3 months. The stock was trading at ₹2,532.00 on 09 Jul 2026 and is currently at ₹2,377.20 as of 09 Oct 2026, reflecting a Loss of ₹154.80 per share over this period.

What was today's high for Mankind Pharma Limited share?

The intraday high for Mankind Pharma Limited on the NSE today (09 Oct 2026) was ₹2,389.80. This compares to the 52-week high of ₹2,642.00 recorded on 29 Jul 2026. Today's high was -9.55% below the 52-week high.

How much return has Mankind Pharma Limited given in the last 52 weeks?

Mankind Pharma Limited has delivered -4.01% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,642.00 on 29 Jul 2026 and a 52-week low of ₹1,909.70 on 23 Mar 2026. It is currently trading at ₹2,377.20 as of 09 Oct 2026.

What is the highest Mankind Pharma Limited share price ever recorded and when?

The all-time high (ATH) for Mankind Pharma Limited was ₹2,998.40, recorded on 23 Dec 2024. At the current price of ₹2,377.20, the stock is trading 20.72% below its all-time high. The all-time low recorded was ₹1,322.65 on 24 May 2023.

What is the return of Mankind Pharma Limited in the past 5 years?

Mankind Pharma Limited has delivered a N/A% absolute return over the past 5 years, equivalent to a CAGR of N/A% per annum. The stock was priced at ₹N/A in Oct 2021 and has fallen to ₹2,377.20 as of 09 Oct 2026. An investment of ₹1,00,000 in Mankind Pharma Limited five years ago would be worth ₹N/A today.

Has Mankind Pharma Limited offered any dividend in the past 5 years?

No,Mankind Pharma Limited has not declared any dividend over the past 5 years. The company paid a total dividend of 1.00 per share between FY2022 and FY2026, with the most recent dividend of ₹1.00 per share for Jul 25, with an ex-dividend date of 08 Aug 2025. At the current market price of ₹2,377.20, the trailing dividend yield of Mankind Pharma Limited stands at 1.00%.